Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 15/20 | 1.00 |
| ▸ | JAK2 | O60674 | 13/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19551082 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL29391999 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL29395478 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL18662687 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2 | |
| SCHEMBL29394791 | 0.93 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL18662586 | 0.93 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL19551129 | 0.93 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL18662707 | 0.93 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL29392563 | 0.93 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL25408214 | 0.89 | JAK1 (1.00) | JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353168-B1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | claimed |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-04-21 | — | — | US | claimed |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-15 | — | — | US | claimed |
| US-20210078981-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-03-18 | — | — | US | claimed |
| CN-111848586-A | Compounds and methods for inhibiting JAK | 迪哲（江苏）医药有限公司 | 2020-10-30 | — | — | CN | claimed |
| US-10167276-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2019-01-01 | — | — | US | claimed |
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | claimed |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | US | claimed |
| EP-3353168-B1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-4219482-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219482-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| WO-2017050938-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | WO | disclosed |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | US | disclosed |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885TYK2 40/4885 |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885TYK2 40/4885 |
| US-20210078981-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885TYK2 40/4885 |
| US-10167276-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885TYK2 40/4885 |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885TYK2 40/4885 |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885TYK2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.